Does Lacosamide Cross the Placenta?
Lacosamide, an antiepileptic drug (AED) used for partial-onset seizures, crosses the human placenta. Studies show fetal plasma concentrations average 66% (range 30-90%) of maternal levels at birth, exposing the fetus throughout pregnancy.[1][2]
Major Birth Defect Risks
Human data from pregnancy registries indicate no significant increase in major congenital malformations with lacosamide monotherapy compared to the general population (2-3% baseline risk). Pooled analyses of 1,000+ exposures report malformation rates of 2.5-4.6%, similar to other AEDs like levetiracetam but lower than older drugs like valproate (10%).[3][4] Animal studies (rats, rabbits) at high doses showed skeletal variations and reduced fetal weight, but no teratogenic effects at human-equivalent exposures.[5]
Neurodevelopmental Outcomes
Limited long-term data exists. A 2022 study of 39 lacosamide-exposed children found normal cognitive scores at age 3-5, with no increase in autism or ADHD signals versus unexposed controls. Dose-dependent risks cannot be ruled out, as most data involve polytherapy.[6] Epilepsy itself raises neurodevelopmental risks by 1.5-2x, complicating attribution.[7]
Preterm Birth and Growth Effects
Lacosamide exposure links to slightly higher preterm birth (10-15% vs. 8% baseline) and low birth weight in some cohorts, possibly due to maternal epilepsy severity rather than the drug alone. No consistent growth restriction noted.[3][8]
Pregnancy Category and Recommendations
FDA classifies lacosamide as Pregnancy Category C (animal risks, inadequate human data). ACOG and AES recommend it as a lower-risk AED for women of childbearing potential, preferring monotherapy at the lowest effective dose (<400 mg/day). Folic acid supplementation (0.4-4 mg/day) is advised to mitigate AED-related neural tube defects.[9][10]
Monitoring and Management During Pregnancy
- Track serum levels: Clearance rises 30-50% in third trimester, requiring dose adjustments.[2]
- Fetal ultrasounds: Standard anomaly scans at 18-20 weeks.
- Postnatal: Infant monitoring for withdrawal (irritability, tremors, rare).
Breastfeeding is compatible; levels in milk are low (~15% of maternal dose).[11]
Compared to Other AEDs
| AED | Major Malformation Risk | Key Concerns |
|-----|--------------------------|--------------|
| Lacosamide | 2-5% | Limited data, growth effects? |
| Levetiracetam | 2-3% | Similar profile, more data |
| Lamotrigine | 2-3% | Best-studied newer AED |
| Valproate | 10% | Avoid if possible |
| Topiramate | 4-6% | Oral clefts |
Lacosamide ranks favorably among newer AEDs but lacks lamotrigine/levetiracetam's exposure volume.[4][12]
Sources
[1] EURAP Study on Lacosamide Placental Transfer
[2] Lacosamide Pharmacokinetics in Pregnancy
[3] NAAP Registry: Lacosamide Outcomes
[4] UK Epilepsy Pregnancy Register
[5] Vimpat Prescribing Information
[6] Neurodevelopment in Lacosamide-Exposed Children
[7] Epilepsy and Offspring Risks Meta-Analysis
[8] Prospective Cohort on AEDs and Preterm Birth
[9] ACOG Guidelines on Epilepsy in Pregnancy
[10] AES Practice Advisory
[11] Lacosamide in Breast Milk
[12] Comparative AED Teratogenicity Review